Revibe Technologies Announces Clinical Development Updates for its Investigational FokusRx Prescription Digital Therapy for the Treatment of ADHD

Revibe Technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school-aged children with attention deficit hyperactivity disorder (ADHD). FokusRx is an investigational SaMD (Software as a Medical Device) that has the potential to provide a new nonpharmacologic approach to treating attention, focus, and hyperactivity deficits associated with ADHD, and other mental health conditions.
Read more...

;